Development of the CGRP antagonist Telcagepant will not be continued
Merck halts clinical development program for CGRP antagonist telcagepant. A new therapeutic mechanism for migraine treatment was developed for clinical application with the CGRP antagonists MK-0974 and MK-3207. These are two drugs currently undergoing clinical research programs [...]


_04-320x202.jpg)